203 related articles for article (PubMed ID: 10738037)
1. Successful mobilization of peripheral blood HPCs with G-CSF alone in patients failing to achieve sufficient numbers of CD34+ cells and/or CFU-GM with chemotherapy and G-CSF.
Fraipont V; Sautois B; Baudoux E; Pereira M; Fassotte MF; Hermanne JP; Jérusalem G; Longrée L; Schaaf-Lafontaine N; Fillet G; Beguin Y
Transfusion; 2000 Mar; 40(3):339-47. PubMed ID: 10738037
[TBL] [Abstract][Full Text] [Related]
2. Stem cell mobilization with G-CSF alone in breast cancer patients: higher progenitor cell yield by delivering divided doses (2 x 5 microg/kg) compared to a single dose (1 x 10 microg/kg).
Kröger N; Zeller W; Hassan HT; Krüger W; Gutensohn K; Löliger C; Zander AR
Bone Marrow Transplant; 1999 Jan; 23(2):125-9. PubMed ID: 10197796
[TBL] [Abstract][Full Text] [Related]
3. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ
Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017
[TBL] [Abstract][Full Text] [Related]
4. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
Weaver CH; Schulman KA; Buckner CD
Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
[TBL] [Abstract][Full Text] [Related]
5. Mobilizing peripheral blood stem cells with high-dose G-CSF alone is as effective as with Dexa-BEAM plus G-CSF in lymphoma patients.
Kröger N; Zeller W; Fehse N; Hassan HT; Krüger W; Gutensohn K; Lölliger C; Zander AR
Br J Haematol; 1998 Sep; 102(4):1101-6. PubMed ID: 9734664
[TBL] [Abstract][Full Text] [Related]
6. Application of whole blood and peripheral blood progenitor cells (PBPC) and new strategies for rescue after intensive cyclic chemotherapy in high-risk breast cancer.
Filip S; Bláha M; Odrázka K; Mericka P; Vávrová J
J Hematother Stem Cell Res; 2000 Feb; 9(1):31-8. PubMed ID: 10738969
[TBL] [Abstract][Full Text] [Related]
7. Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF.
Koç ON; Gerson SL; Cooper BW; Laughlin M; Meyerson H; Kutteh L; Fox RM; Szekely EM; Tainer N; Lazarus HM
J Clin Oncol; 2000 May; 18(9):1824-30. PubMed ID: 10784622
[TBL] [Abstract][Full Text] [Related]
8. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
9. Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells.
Hohaus S; Martin H; Wassmann B; Egerer G; Haus U; Färber L; Burger KJ; Goldschmidt H; Hoelzer D; Haas R
Bone Marrow Transplant; 1998 Oct; 22(7):625-30. PubMed ID: 9818688
[TBL] [Abstract][Full Text] [Related]
10. Peripheral blood stem cell mobilization with cyclophosphamide in combination with G-CSF, GM-CSF, or sequential GM-CSF/G-CSF in non-Hodgkin's lymphoma patients: a randomized prospective study.
Gazitt Y; Callander N; Freytes CO; Shaughnessy P; Liu Q; Tsai TW; Devore P
J Hematother Stem Cell Res; 2000 Oct; 9(5):737-48. PubMed ID: 11091498
[TBL] [Abstract][Full Text] [Related]
11. CD34+ cells mobilized by cyclophosphamide and granulocyte colony-stimulating factor (G-CSF) are functionally different from CD34+ cells mobilized by G-CSF.
Cesana C; Carlo-Stella C; Regazzi E; Garau D; Sammarelli G; Caramatti C; Tabilio A; Mangoni L; Rizzoli V
Bone Marrow Transplant; 1998 Mar; 21(6):561-8. PubMed ID: 9543059
[TBL] [Abstract][Full Text] [Related]
12. Factors influencing G-CSF-mediated mobilization of hematopoietic progenitor cells during steady-state hematopoiesis in patients with malignant lymphoma and multiple myeloma.
Kobbe G; Söhngen D; Bauser U; Schneider P; Germing U; Thiele KP; Rieth C; Hünerlitürkoglu A; Fischer J; Frick M; Wernet P; Aul C; Heyll A
Ann Hematol; 1999 Oct; 78(10):456-62. PubMed ID: 10550556
[TBL] [Abstract][Full Text] [Related]
13. Successful mobilization of peripheral blood stem cells in heavily pretreated myeloma patients with G-CSF alone.
Kröger N; Zeller W; Hassan HT; Krüger W; Renges H; Hummel K; Gutensohn K; Lölliger C; Zander AR
Ann Hematol; 1998 Jun; 76(6):257-62. PubMed ID: 9692813
[TBL] [Abstract][Full Text] [Related]
14. Matched-pair analysis of hematopoietic progenitor cell mobilization using G-CSF vs. cyclophosphamide, etoposide, and G-CSF: enhanced CD34+ cell collections are not necessarily cost-effective.
Akard LP; Thompson JM; Dugan MJ; Wiemann M; Greenspan A; Hanks S; Swinney M; Nyhuis A; Jansen J
Biol Blood Marrow Transplant; 1999; 5(6):379-85. PubMed ID: 10595815
[TBL] [Abstract][Full Text] [Related]
15. Is there any difference in PBPC mobilization between cyclophosphamide plus G-CSF and G-CSF alone in patients with non-Hodgkin's Lymphoma?
Dazzi C; Cariello A; Rosti G; Argnani M; Sebastiani L; Ferrari E; Zornetta L; Monti G; Nicoletti P; Baioni M; Salvucci M; Scarpi E; Marangolo M
Leuk Lymphoma; 2000 Oct; 39(3-4):301-10. PubMed ID: 11342310
[TBL] [Abstract][Full Text] [Related]
16. Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF.
Engelhardt M; Winkler J; Waller C; Lange W; Mertelsmann R; Henschler R
Bone Marrow Transplant; 1997 Mar; 19(6):529-37. PubMed ID: 9181898
[TBL] [Abstract][Full Text] [Related]
17. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma.
Moskowitz CH; Glassman JR; Wuest D; Maslak P; Reich L; Gucciardo A; Coady-Lyons N; Zelenetz AD; Nimer SD
Clin Cancer Res; 1998 Feb; 4(2):311-6. PubMed ID: 9516916
[TBL] [Abstract][Full Text] [Related]
18. Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone.
Alegre A; Tomás JF; Martínez-Chamorro C; Gil-Fernández JJ; Fernández-Villalta MJ; Arranz R; Díaz MA; Granda A; Bernardo MR; Escudero A; López-Lorenzo JL; Fernández-Rañada JM
Bone Marrow Transplant; 1997 Aug; 20(3):211-7. PubMed ID: 9257889
[TBL] [Abstract][Full Text] [Related]
19. Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma.
Demirer T; Buckner CD; Gooley T; Appelbaum FR; Rowley S; Chauncey T; Lilleby K; Storb R; Bensinger WI
Bone Marrow Transplant; 1996 Jun; 17(6):937-41. PubMed ID: 8807097
[TBL] [Abstract][Full Text] [Related]
20. Analysis of platelet recovery after autologous transplantation with G-CSF mobilized CD34+ cells purified from leukapheresis products.
Hermouet S; Niaussat AE; Briec A; Pineau D; Robillard N; Bataille R; Milpied N; Harousseau JL; Mahé B
Hematol Cell Ther; 1997 Dec; 39(6):317-25. PubMed ID: 9497891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]